Back to Authors

O’Brien, Bridget

Mayo Clinic

Rush University

Citations 1

Integrating oncology advanced practice providers and clinical pharmacists into clinical cancer research
Braun‐Inglis, Christa , Myers, Jamie, O’Brien, Bridget, Kottschade, Lisa A. , Flannery, Marie , DeTroye, Alisha , Elko, Theresa A. , Leatherwood, Amy, Mader, Alyssa, Wong, Siu Fun, Foust, Melyssa , Benson, Al B., Primeaux, Brian , Demirhan, Kimberly , Statler, Tiffany, Vogel, Wendy , Kottschade, Lisa, Braun-Inglis, Christa M , Myers, Jamie , O'Brien, Bridget, Leatherwood, Amy Eiko , Bakitas, Marie , Benson, Al B. , Berenberg, Jeffrey L. , Rosenzweig, Margaret Quinn , Statler, Tiffany M. , Sun, Virginia Chih-Yi

JNCI: Journal of the National Cancer Institute | April 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag125 Get It

Abstract Oncology Advanced Practice Providers (APPs), including Advanced Practice Registered Nurses, Physician Assistants, and Clinical Pharmacists (CPs), play a vital role in delivering high-quality, patient-centered cancer care across the United States. Despite their widespread presence in oncology practices, APPs remain underutilized in cancer clinical research, representing a missed opportunity to expand trial access and improve patient outcomes. Clinical trials are essential to advancing oncology care, yet participation remains critically low among adult patients. Given Oncology APPs’ and CPs’ central role in cancer care delivery, their meaningful engagement in oncology clinical trial research is imperative as the standard of oncology care. This position article, with contributions from 5 professional societies, presents solutions and resources to barriers limiting APPs’ and CPs’ involvement in cancer clinical research, including gaps in education, role expectations, limited protected time, restrictive policies, insufficient financial support, and underrecognition of contributions. Integrating APPs and CPs more fully into the clinical research enterprise is essential to improving trial access, patient outcomes, closing equity gaps, and accelerating innovation in oncology care.